Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial.
Stein A, Paschold L, Tintelnot J, Goekkurt E, Henkes SS, Simnica D, Schultheiss C, Willscher E, Bauer M, Wickenhauser C, Thuss-Patience P, Lorenzen S, Ettrich T, Riera-Knorrenschild J, Jacobasch L, Kretzschmar A, Kubicka S, Al-Batran SE, Reinacher-Schick A, Pink D, Sinn M, Lindig U, Hiegl W, Hinke A, Hegewisch-Becker S, Binder M. Stein A, et al. JAMA Oncol. 2022 Aug 1;8(8):1150-1158. doi: 10.1001/jamaoncol.2022.2228. JAMA Oncol. 2022. PMID: 35737383 Free PMC article. Clinical Trial.
[Adjuvant therapy of colon carcinoma].
Trarbach T, Kubicka S, Hacker U, Ridwelski K, Reinacher-Schick A. Trarbach T, et al. Onkologie. 2008;31 Suppl 5:19-23. doi: 10.1159/000163072. Epub 2008 Nov 14. Onkologie. 2008. PMID: 19033700 Review. German.
[Adjuvant therapy in colon cancer].
Reinacher-Schick A, Arnold D, Trarbach T, Ridwelski K, Bruch HP, Kirchner T, Kubicka S, Schmoll HJ. Reinacher-Schick A, et al. Onkologie. 2010;33 Suppl 4:2-7. doi: 10.1159/000308436. Epub 2010 Apr 23. Onkologie. 2010. PMID: 20431306 Review. German.
[Gastrointestinal tumors--interdisciplinary discussion over new data].
Arnold D, Fietkau R, Hegewisch-Becker S, Höhler T, Knoefel WT, Kubicka S, Lang H, Liersch T, Luster M, Oettle H, Reinacher-Schick A, Ridwelski K, Riess H, Rödel C, Rüschoff J, Schmiegel W, Schmoll HJ, Vanhoefer U. Arnold D, et al. Onkologie. 2011;34 Suppl 3:1-31. doi: 10.1159/000328047. Epub 2011 Apr 27. Onkologie. 2011. PMID: 21577036 Free article. German. No abstract available.
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D. Hegewisch-Becker S, et al. Lancet Oncol. 2015 Oct;16(13):1355-69. doi: 10.1016/S1470-2045(15)00042-X. Epub 2015 Sep 8. Lancet Oncol. 2015. PMID: 26361971 Clinical Trial.
Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.
Hegewisch-Becker S, Nöpel-Dünnebacke S, Hinke A, Graeven U, Reinacher-Schick A, Hertel J, Lerchenmüller CA, Killing B, Depenbusch R, Al-Batran SE, Lange T, Dietrich G, Tannapfel A, Arnold D. Hegewisch-Becker S, et al. Eur J Cancer. 2018 Sep;101:105-113. doi: 10.1016/j.ejca.2018.06.015. Epub 2018 Jul 20. Eur J Cancer. 2018. PMID: 30036739 Clinical Trial.
Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial.
Noepel-Duennebacke S, Arnold D, Hertel J, Tannapfel A, Hinke A, Hegewisch-Becker S, Reinacher-Schick A. Noepel-Duennebacke S, et al. Clin Colorectal Cancer. 2018 Dec;17(4):e733-e739. doi: 10.1016/j.clcc.2018.07.007. Epub 2018 Jul 25. Clin Colorectal Cancer. 2018. PMID: 30145148 Clinical Trial.
Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial.
Stintzing S, Ivanova B, Ricard I, Jung A, Kirchner T, Tannapfel A, Juette H, Hegewisch-Becker S, Arnold D, Reinacher-Schick A. Stintzing S, et al. Front Oncol. 2018 Nov 8;8:474. doi: 10.3389/fonc.2018.00474. eCollection 2018. Front Oncol. 2018. PMID: 30467535 Free PMC article.
175 results